Dubnov‐Raz 2011.

Methods	A case‐control study of 17 months of methylphenidate treatment using a chart review of computerised medical records
Participants	Number of participants screened: 529 Number of participants included: 275 Number included as cases: 135 (methylphenidate treated) and controls: 140 (untreated) Diagnosis of ADHD: DSM‐IV‐TR (subtype: not stated) Age: mean 10.4 years old, range 6‐16 IQ: > 70 Sex: 200 males, 75 females Methylphenidate‐naïve: cases (none), controls (100%) Ethnicity: multiethnic Country: Israel Comorbidity: none Comedication: none Sociodemographics: a variety of different family patterns and socioeconomic status among the groups. Those who were already methylphenidate treated were 7 months older, on average, than the methylphenidate‐naïve patients, and they had a higher proportion of males. Weight, height, and body mass index z scores, which inherently correct for age and sex, did not differ significantly between these 2 subgroups. Rates of overweight and obesity were also comparable Inclusion criteria 6‐16 years old DSM‐IV‐TR diagnosis of ADHD Treated in the ADHD clinic of the Neuro‐paediatric Unit, Hadassah Medical Center, from 1 January 2004 to 31 December 2008 Exclusion criteria Presence of additional mental or somatic chronic health conditions (e.g. epilepsy, mental retardation, cerebral palsy, prior significant brain injury, hearing/visual impairments, pervasive developmental disorder, mental disorders) other than overweight Use of dietary supplements or chronic medications (other than methylphenidate)
Interventions	Methylphenidate type: regular (n = 52), slow‐release/long‐acting (n = 61), or osmotic release oral system (n = 22) Baseline methylphenidate mean dose: 0.43 mg/kg (SD 0.22), range: 0.1‐1.0 mg/kg (each 4.5 mg of osmotic release was regarded as 1 mg methylphenidate) Administration schedule: not stated Duration of intervention: not stated Treatment compliance: not stated
Outcomes	Height and weight measured by a certified nurse at baseline and follow‐up visits Body mass index
Notes	Sample calculation: not stated Ethics approval: yes Funding/vested interests: the authors received no financial support for the research and/or authorship of this article Key conclusions of the study authors: physicians should be aware of the possibility of height and weight abnormalities in children with ADHD, with or without treatment Comments from the review authors: only the data on the methylphenidate‐treated and untreated participants with ADHD are used in this review Supplemental information requested from the authors in July 2013, but they did not have the time to find the relevant information